Atherosclerosis, a chronic inflammation of the vessel wall, is a major cause for vascular mortality due to narrowing (stenosis) of the arterial wall. In part, artery stenosis is therapeutically addressed by widening the vessel through angioplasty. Although well-established, angioplasty can damage the arterial endothelium, giving rise to an inflammatory response that leads to a neointimal hyperplasia with consequent recurrence of stenosis.[1] [2] Key players in this process are leukocytes and smooth muscle cells (SMCs), as leukocyte recruitment and SMC proliferation and migration are determinants of neointimal hyperplasia.[3] MFGE8 (milk fat globule-epidermal growth factor 8) or lactadherin is mostly regarded as a bridging molecule with a critical function in efferocytosis and, hence, during resolution of inflammation.[4] However, MFGE8 also plays a major role in promoting neovascularization,[5] and, more recently, arterial MFGE8 expression emerged as a molecular hallmark of adverse cardiovascular remodelling upon aging.[6] In this context, MFGE8 is directly associated with SMC proliferation and migration,[6] [7] suggesting its participation in neointima formation. We here show that MFGE8 negatively impacts on arterial restenosis and its neutralization may therefore be a potential therapeutic strategy. To study the role of MFGE8 in arterial restenosis, we subjected two groups of mice, Apoe−/− and Apoe−/−Mfge8−/− , to wire injury of the left carotid artery. To simulate hypercholesterolemia, a condition often present in atherosclerotic patients, the mice were fed a high-fat diet, starting 1 week prior to injury. Two weeks after the injury, the mice were euthanized and the blood and carotids were collected. To assess neointima formation, the carotids were stained for elastic tissue fibres with Verhoeff–Van Gieson stain. Neointima area was significantly smaller throughout the injured carotid in mice lacking MFGE8 as compared with the Apoe−/− group ([Fig. 1A]–[C]). No differences in blood counts were observed between the groups ([Supplementary Table S1], available in the online version), suggesting that the distinct neointima areas are mediated by local cells. However, cholesterol levels in the blood were higher in Apoe−/−Mfge8−/− mice as compared with Apoe−/− , likely a consequence of decreased fatty acid uptake by the liver as well as small intestine, as MFGE8 has been reported to promote fatty acid uptake.[8] [9] To determine which cells contributed the most for the larger neointima observed in Apoe−/− mice, we stained the carotids with antibodies against macrophages and SMCs, since MFGE8 has been reported to be expressed in these cells.[10] [11] Lack of MFGE8 did not affect neointimal macrophages, while SMC areas were vastly reduced ([Fig. 1D], [E]). To assess whether this was the result of reduced cell proliferation, the carotid arteries were stained with an antibody against Ki67, a cellular marker of proliferation. The staining revealed significantly less SMC proliferation in mice lacking MFGE8 as compared with their wild-type littermates, suggesting a determinant role of lactadherin in restenosis formation. To confirm this observation, and verify MFGE8 as a therapeutic target, we subjected Apoe−/− mice to arterial injury combined with the local application of siRNA, either against MFGE8 or scrambled. siRNA against MFGE8 resulted in 50% reduced expression of the protein both in the intima and in the neointima (lesion) area of the carotid artery ([Supplementary Fig. S1], available in the online version). Similar to what was observed in the knockout animal models, analysis of the injured carotids of mice treated with siRNA directed to MFGE8 showed a decreased neointima sizes as compared with mice treated with control siRNA ([Fig. 1G]–[I]). Equally in accordance with the studies in the knockout animal models, no differences in blood counts were observed between the groups ([Supplementary Table S1], available in the online version). Blood cholesterol levels remained unchanged ([Supplementary Fig. S2], available in the online version), supporting the argument presented earlier for the difference observed in the blood of the knockout animal models: since the siRNA effect is strictly local, it does not affect fatty acid uptake. Consistent with the observations in the carotids of Apoe−/− versus Apoe−/−Mfge8−/− mice, the administration of siRNA against MFGE8 affected SMCs' content in the neointima ([Fig. 1K]) and its proliferation ([Fig. 1L]) but the macrophage composition remained unchanged ([Fig. 1J]). Overall, these results strongly point toward a relevant role of MFGE8 in postinjury arterial wall remodelling, with the potential to be exploited for therapeutic purposes. Our studies suggest these effects to be SMC-mediated, more specifically: by stimulating SMC proliferation, MFGE8 promotes the formation of neointima possibly leading to hyperplasia and consequent stenosis. Note: The review process for this paper was fully handled by Gregory Y. H. Lip, Editor-in-Chief.